Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Lilly to Invest Additional 20 Billion Yen in Japan's Seishin Plant
Eli Lilly Japan said on March 12 that it will invest an additional 20 billion yen in its Seishin plant in Kobe to ramp up domestic production capacity, citing rising demand for existing products and upcoming launches in obesity, diabetes,…
To read the full story
Related Article
- Lilly Breaks Ground on New Building at Kobe Plant
June 15, 2026
- Lilly Japan Ramps Up Seishin Plant with New Building and Packaging Line
September 9, 2025
BUSINESS
- Sanwa Kagaku on Track to Resume Kumamoto Production in October
October 13, 2026
- Toho Drops PHC Buyout Bid, Still Exploring Growth Options
October 13, 2026
- Terumo to Take US$610 Million Hit as CSL Plasma Supply Deal Ends
October 9, 2026
- TOPIX Shuffle Puts Mid-Tier Drug Makers, Wholesalers on Chopping Block
October 9, 2026
- Ono Gets Japan, Asia Rights to 3 IgG Degraders from Biohaven
October 9, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…